Aim immunotech completes treatment of last subject in phase 2 study evaluating ampligen® for the treatment of post-covid conditions

No severe adverse events reported to date topline data expected as early as q1 2024 ocala, fla., nov. 21, 2023 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”) today announced the last subject has completed treatment in the company's phase 2 study evaluating ampligen® as a potential therapeutic for people with the post-covid condition of fatigue (“amp-518”).
AIM Ratings Summary
AIM Quant Ranking